Stock Research: Aspen Pharmacare

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Aspen Pharmacare

JSE:APN ZAE000066692
32
  • Value
    38
  • Growth
    9
  • Safety
    Safety
    99
  • Combined
    40
  • Sentiment
    22
  • 360° View
    360° View
    32
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Aspen Pharmacare Holdings Limited is a global pharmaceutical company. It focuses on marketing and manufacturing a range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets, including the key brands Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon, and Xylocaine. Aspen Pharmacare Holdings Limited operates in South Africa and other global markets. In the last fiscal year, the company had a market cap of $2,813 million, profits of $1,070 million, revenue of $2,458 million, and 8,867 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 32 (better than 32% compared with alternatives), overall professional sentiment and financial characteristics for the stock Aspen Pharmacare are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Aspen Pharmacare. Only the consolidated Value Rank has an attractive rank of 99, which means that the share price of Aspen Pharmacare is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 99% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 9, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 38, meaning the company has a riskier financing structure than 62% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 78% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 22. ...read more

more
Index
Good Governace Growth Markets
JSE All Shares
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
99 91 99 89
Growth
9 27 45 77
Safety
Safety
38 39 41 7
Sentiment
22 71 90 55
360° View
360° View
32 65 88 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
9 73 79 46
Opinions Change
61 23 72 50
Pro Holdings
n/a 80 73 26
Market Pulse
17 70 42 81
Sentiment
22 71 90 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
99 91 99 89
Growth
9 27 45 77
Safety Safety
38 39 41 7
Combined
40 53 75 71
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
95 97 93 81
Price vs. Earnings (P/E)
89 77 82 78
Price vs. Book (P/B)
91 89 91 91
Dividend Yield
88 82 81 76
Value
99 91 99 89
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
36 26 54 78
Profit Growth
10 39 48 76
Capital Growth
22 45 21 21
Stock Returns
5 39 79 79
Growth
9 27 45 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
23 24 34 36
Refinancing
96 88 90 1
Liquidity
22 24 28 24
Safety Safety
38 39 41 7

Similar Stocks

Discover high‑ranked alternatives to Aspen Pharmacare and broaden your portfolio horizons.

Exxaro

JSE:EXX
Country: South Africa
Industry: Coal & Consumable Fuels
Size: Medium
Full Stock Analysis

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Tiger Brands

JSE:TBS
Country: South Africa
Industry: Packaged Foods & Meats
Size: Medium
Full Stock Analysis

Harmony

JSE:HAR
Country: South Africa
Industry: Gold Production
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.